| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8906938 | CHEMOCENTRYX | C5aR antagonists |
Dec, 2029
(6 years from now) | |
| US8445515 | CHEMOCENTRYX | C5aR antagonists |
Feb, 2031
(7 years from now) | |
| US11603356 | CHEMOCENTRYX | Amorphous form of a complement component C5a receptor |
May, 2041
(17 years from now) | |
Tavneos is owned by Chemocentryx.
Tavneos contains Avacopan.
Tavneos has a total of 3 drug patents out of which 0 drug patents have expired.
Tavneos was authorised for market use on 07 October, 2021.
Tavneos is available in capsule;oral dosage forms.
Tavneos can be used as an adjunctive treatment of adult patients with tavneos (avacopan) with severe active anca-associated vasculitis (gpa and mpa) in combination with standard therapy including glucocorticoids.
Drug patent challenges can be filed against Tavneos from 2025-10-07.
The generics of Tavneos are possible to be released after 29 May, 2041.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Oct 7, 2028 |
| New Chemical Entity Exclusivity (NCE) | Oct 7, 2026 |
Drugs and Companies using AVACOPAN ingredient
NCE-1 date: 2025-10-07
Market Authorisation Date: 07 October, 2021
Treatment: An adjunctive treatment of adult patients with tavneos (avacopan) with severe active anca-associated vasculitis (gpa and mpa) in combination with standard therapy including glucocorticoids
Dosage: CAPSULE;ORAL
TAVNEOS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic